Next Article in Journal
Opioids in the Treatment of Chronic Idiopathic Diarrhea in Humans—A Systematic Review and Treatment Guideline
Previous Article in Journal
App-Based Mindfulness Meditation Training and an Audiobook Intervention Reduce Symptom Severity but Do Not Modify Backward Inhibition in Adolescent Obsessive-Compulsive Disorder: Evidence from an EEG Study
Previous Article in Special Issue
Evolving Role of [18F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 7
10.3390/jcm12072487
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Dark Side of Ultrasound Imaging in Parathyroid Disease

by
Roberta Centello
1,†,
Franz Sesti
1,†,
Tiziana Feola
1,2,
Valentina Sada
1,
Carla Pandozzi
1,
Marco Di Serafino
3,4,
Patrizia Pacini
5,
Vito Cantisani
5,
Elisa Giannetta
1,* and
Maria Grazia Tarsitano
6
1
Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy
2
Neuroendocrinology, Neuromed Institute, IRCCS, 86077 Pozzilli, Italy
3
General and Emergency Radiology Department, “Antonio Cardarelli” Hospital, 80131 Naples, Italy
4
Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, 86100 Campobasso, Italy
5
Department of Radiological Sciences, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy
6
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2023, 12(7), 2487; https://doi.org/10.3390/jcm12072487
Submission received: 13 February 2023 / Revised: 14 March 2023 / Accepted: 23 March 2023 / Published: 24 March 2023
(This article belongs to the Special Issue Imaging in Endocrine Diseases and Neuroendocrine Tumors)
Browse Figures
Versions Notes

Abstract

:
The diagnosis of parathyroid diseases by imaging still has some intrinsic technical limitations due to the differential diagnosis of different structures of the neck that mimic the parathyroid glands. In this view, ultrasound (US) is an established, low-cost, and non-invasive imaging technique that still represents the first-line approach for evaluating patients with parathyroid disease. The objective of this article is to provide a comprehensive review of the applications of USs in clinical practice, discussing the histopathological and US characteristics of the parathyroid glands in normal and pathological conditions, the advantages of preoperative imaging, and novel updates on the most useful and currently available multiparameter US techniques.

1. Introduction

Ultrasound (US) is considered the gold-standard diagnostic tool for neck organic disorders. In fact, the high-resolution and dynamic nature of this low-cost and non-invasive technique perfectly matches the superficial but complex anatomy of the neck, allowing the operator to obtain precise anatomic details and to identify pathological lesions in most cases [1].
Against this background, parathyroid disease still remains a diagnostic dilemma on US evaluation. In fact, whereas the clinical and biochemical diagnoses of altered parathyroid glands’ (PGs) function is in most cases straightforward, the radiological identification of the pathological glands, just like that of normal ones, can be arduous.
In case of hyperfunctioning PG(s), a clinical syndrome known as hyperparathyroidism (HPT) occurs, whose surgical-treatment planning is the main indication for performing imaging techniques to locate pathological parathyroid tissue.
As guidelines suggest, the aim of pre-operative parathyroid imaging is to achieve two concordant results from different imaging techniques. The combination of cervical US and nuclear imaging [i.e., 99mTechnetium (99mTc)-Sestamibi scintigraphy or single-photon emission computed tomography/computed tomography (SPECT/CT)] is acknowledged as the most widely used first-line strategy [2].
Cervical USs are performed with a high-frequency linear probe by transverse and longitudinal scanning of the neck, focusing on the paratracheal spaces and the carotid-jugular axis up to the carotid bifurcation and down to the sternal notch [3]. This technique presents clear technical advantages and good diagnostic accuracy, to the point that it has been recently advocated that it could be used as a main and sole investigation in the majority of patients [4]. Nonetheless, the US identification of parathyroid lesions can be difficult in many cases. This is mainly due to the morpho-pathological heterogeneity existing in the PGs disorders and to the numerous cervical lesions of other natures representing pitfalls to be aware of in the process of differential diagnosis. Moreover, an US’s ability to correctly identify enlarged PGs can be influenced and undermined by different factors, such as the presence of an ectopic PG below the VI neck level, a concomitant nodular thyroid disease, a prior anterior neck surgical procedure, or an unsuitable operator experience, which alone can account for as much as a 40% variation in the US sensitivity [2,5]. Yet in HPT affected patients, an accurate preoperative identification and localization of all hyperfunctioning glands by imaging methods is necessary not only for a more focused surgical approach (i.e., minimally invasive parathyroidectomy) with a subsequent reduction of surgery duration and complications compared with classical bilateral neck exploration, but also for long-term surgical success [6]. In these scenarios, nuclear-imaging investigations should be adopted. Besides the aforementioned traditional techniques, more recently positron emission tomography (PET)/CT using the radiotracer 18F-fluorocholine is emerging for its superior spatial resolution, lower radiation burden and shorter scanning time, and has been proposed as an alternative first-line “one-stop-shop” imaging method [7,8,9]. However, data on cost-effectiveness are currently lacking, and US remains the most useful available technique.
In recent years a multiparametric US approach has been adopted thanks to the introduction of some innovative problem-solving modalities which have further improved the ability of lesion characterization, offering greater diagnostic accuracy and leading to an increasingly important role of USs in clinical decision making. A multimodal US pathway includes, besides the traditional B-mode grey-scale and Color Doppler US, contrast-enhanced US (CEUS) and US-elastography (USE) [10,11,12].
CEUS is an approved, safe method consisting of the intravenous injection of a microbubble contrast agent during an US performance-detecting tissues characteristic microvascularization pattern [13,14,15]. The use of quantitative post-processing software tools, overcoming the limit of the subjective examiner’s interpretation, improves this technique’s diagnostic role, facilitating the differential diagnosis between parathyroid lesions and other mimicking structures with an accuracy of 96.4% [16,17].
USE refers to different dynamic technologies which non-invasively assess tissue elasticity through mild tissue deformation (strain USE) or sending focused acoustic impulses from modified transducers (shear-wave USE). Some authors demonstrated that USE may be a useful additional tool to improve the preoperative US detection of parathyroid lesions, as well as in discriminating between benign and malignant lesions [18,19,20].
However, to date there are no specific guidelines for the use of CEUS or USE for the evaluation of the PGs, and only sparse and incongruous literature data are available.
When, despite all of the available imaging methods, it results difficult to differentiate enlarged PGs from other lesions, US-guided fine-needle aspiration (FNA) cytology and the measurement of the FNA-parathyroid hormone (PTH) could be useful. As reviewed by Trimboli and colleagues, several studies demonstrated the relevance to measure FNA-PTH to localize parathyroid adenomas, reporting a sensitivity of 70–100% and a specificity of 75–100% [21]. However, this procedure is not well standardized, and no consensus exists about the FNA-PTH reference range [2]. Furthermore, it can be burdened with complications, such as post-FNA fibrosis (which makes surgery more difficult and may imitate malignancy on histopathological exam [22]), inflammatory reaction, parathyroid abscess, hematoma [23], parathyromatosis [24], and the potential risk of parathyroid carcinoma seeding [25]. Thus, FNA cytology is not widely recommended.
The aim of the current review is to present an overview of the histopathological and US characteristics of the PGs in normal and pathological conditions, discussing the clear advantages and the challenging aspects of traditional and novel multiparametric US techniques, with selected examples of clinical utility across a variety of lesions to consider for an adequate differential diagnosis.

2. Overview of Parathyroid Anatomy, Physiology, and Pathology

The PGs are endocrine glands responsible for producing PTH, whose principal role is to sustain or increase plasma calcium levels by acting directly on bones and kidneys and indirectly on the intestinal absorption through vitamin D action [26].
In normal conditions, the PGs measure 5 mm in length, 3 mm in anteroposterior diameter, and 1 mm in lateral diameter, and in most of cases four of them can be found: a superior pair typically located posterior to the mid-to-upper portion of the thyroid lobe, and an inferior pair generally found posterior to the lower thyroid pole [27].
However, a variability in the number and location of PGs has been reported. Supernumerary glands can be identified in 2–13% of the population, and because of their embryologic migration their location is variable; the superior glands can be ectopically located in a retropharyngeal or intrathyroidal site, while the inferior pair can be found from the angle of the mandible to the pericardium [28,29,30,31,32].
In general, normal PGs are barely identified on the US examination due to their intrinsic features or factors related to a poor sonographic window, such as in the case of thickened subcutaneous fat tissue and underlying thyroid disease [33]. In patients with HPT, the hyperfunctioning glands become detectable due to their size and echogenicity.
Clinically, three types of HPT can be identified: primary HPT (PHPT), secondary HPT (SHPT), and tertiary HPT (THPT), corresponding from a morphological point of view to a spectrum of parathyroid lesions encompassing hyperplasia, adenoma (benign tumor), atypical tumors (tumor of uncertain malignant potential), and carcinoma [34].
PHPT is the result of an autonomous PTH oversecretion from abnormal PG(s) determining hypercalcemia, hypophosphatemia, and elevated urinary calcium, with potential complications on the skeletal, renal, neurocognitive, and cardiovascular systems [35].
Most PHPT cases occur sporadically, whereas about 5% are associated with a hereditary syndrome, i.e., types 1, 2A, and 4 multiple endocrine neoplasia (MEN) syndromes, HPT-jaw tumor syndrome, familial hypocalciuric hypercalcemia, neonatal severe HPT, and isolated familial HPT [36].
Overall, 80–85% of PHPT cases are caused by a single-gland adenoma [37].
Multiglandular parathyroid disease accounts for 15–20% of cases [37]. Traditionally, this clinicopathological entity has been referred to as “parathyroid hyperplasia”, but such a concept is no longer supported in the context of PHPT due to the fact that the affected glands are usually composed of multiple clonal neoplastic proliferations. Thus, to highlight its germline susceptibility-driven origin, the 2022 WHO Classification replaced the term of PHPT-related parathyroid hyperplasia with “multiglandular parathyroid disease” or “multiglandular parathyroid adenomas” [34]. Multiglandular disease is generally associated with inherited PHPT and should prompt consideration of genetic counseling and testing, as it could influence the management of affected patients [38].
The aforementioned new classification also replaced the term “atypical parathyroid adenoma” with “atypical parathyroid tumor” to indicate a parathyroid neoplasm of uncertain malignant potential, showing some histopathological findings typical of the parathyroid carcinoma (band-forming fibrosis, increased mitotic activity, presence of tumor cells within a thickened capsule) but lacking the definite diagnostic features of malignancy (invasion into adjacent tissues, vascular invasion and/or metastases) [34].
Rarely (<1% of cases) a parathyroid carcinoma is the PHPT’s underlying pathological lesion [37].
SHPT corresponds to a pathophysiological PTH oversecretion from hyperplastic PGs in response to a chronic stimulus that is usually a reduction in the serum calcium concentration due to an underlying chronic disorder (e.g., chronic renal failure, malabsorption syndromes, vitamin D deficiency). Moreover, drugs such as lithium and thiazide diuretics can be associated with increased PTH levels [39]. Whereas PHPT often manifests with a uniglandular disease, SHPT almost always manifests with multiglandular parathyroid disease so that in the current WHO Classification the term “parathyroid hyperplasia” is used primarily in the setting of secondary hyperplasia [34].
THPT reflects the result of a long-standing SHPT in which the stimulated PGs are no longer in a reactive mode but have assumed a quasi-autonomous function, not too dissimilar from PHPT, with the emergence of a PTH-producing adenoma or rarely carcinoma [39,40] and the development of refractory HPT and hypercalcemia, in patients with previously normal serum calcium levels [29,39]. In this condition, patients are consequently exposed to a potential risk of vascular and soft-tissue calcifications, and an adequate therapy may be indicated [41].

3. Ultrasonographic Findings of Parathyroid Glands

As mentioned above, normal PGs are scarcely detected among the structures of the anterior cervical region because of their small size, variable locations, and similar echogenicity to the thyroid gland or the perithyroidal fat tissue.
In normal conditions, in the rare cases where it is visible on the US examination, a PG appears as a very small oval/flat-shaped hypoechoic structure situated posterior to the thyroid lobes, between the trachea and the carotid artery [33,42]. Moreover, with advancing age, the PGs tend to accumulate more fat cells and granules, which probably makes them more echogenic and less conspicuous within the other echogenic adipose tissues of the neck [42].
The usefulness of the US increases in pathological conditions [43]. In fact, hyperfunctioning PGs become more easily identified, usually appearing on the B-mode grey-scale US as enlarged, circumscribed, hypoechoic, oval-shaped lesions, delineated by hyperechoic connective tissue [17] (Figure 1a,b,d and Figure 2a).
The hypoechogenic aspect is due to the reduction of fat tissue components in these lesions [44]. However, they may have various shapes and sometimes present internal anechoic areas with dorsal echo amplification because of cystic degeneration following the retention of colloid secretion or after hemorrhage [45]. Cystic inclusions may be seen in both malignant and benign lesions, but are generally associated with hyperplasia more than adenomas [17].
It is virtually impossible to sonographically differentiate glandular hyperplasia from adenomatous formations. In case of multiglandular disease, more than one symmetrically or asymmetrically enlarged, lobulated gland may be seen [42].
On the Color Doppler US imaging, both adenoma and hyperplasia in most cases show prominent feeding polar vessels entering the pole and then extending around the periphery of the enlarged gland (Figure 1c,e) [46,47].
Similarly to all the other imaging methods, US is less sensitive for the detection of multiglandular- than of single-gland disease as hyperplastic PGs are usually significantly smaller [48].
A systematic review by Ruda et al. including more than 20,000 patients with PHPT reported sensitivities of 78.5%, 16.2%, and 34.9% for single-gland, two-gland, and multiglandular parathyroid disease, respectively [49]. However, compared with nuclear medicine imaging methods such as 99mTc-Sestamibi dual-phase scintigraphy and SPECT/CT, the US still has been reported to have a slight advantage in the localization of hyperplastic PGs. The combination of US and scintigraphy or SPECT/CT could improve the accuracy in localization of parathyroid hyperplasia, and should be considered the first-line method in such cases [50].
As far as for the PHPT pluriglandular involvement, and also for SHPT cases, imaging is not always able to highlight all four glands, mainly due to the morphopathological heterogeneity existing in this disease. However, performing an US examination prior to surgery can be useful to obtain a suggestive cervical map and an evaluation of the thyroid gland and its possible associated lesions [51].
Currently, there are no well-defined US characteristics published in the literature that allow practitioners to distinguish a parathyroid carcinoma from a benign parathyroid tumor. Nonetheless, some US features may raise the suspicion for malignancy: >3 cm length, a depth/width ratio > 1, lobulated hypoechoic/heterogeneous aspect, irregular borders, thick capsule, suspicious vascularity, and intra-nodular calcifications [52,53]. However, these features may also be seen in benign tumors, and thus cannot be decisive for a preoperative diagnosis. Occasionally, the infiltration into surrounding tissues and cervical lymph node enlargement can be identified or suspected [26].
Of note, longstanding SHPT and THPT may be associated with enlarged PGs showing some atypical features that can mimic invasive growth. Thus, caution is urged before a preoperative suspect of parathyroid carcinoma is made in the setting of an advanced chronic renal failure [34].
On CEUS evaluation, parathyroid hyperplasia is characterized by fast intense homogeneous enhancement and a homogeneous wash-out appearance, whereas adenomas show an early peripheral hyperenhancement with central wash-out in the later phases [16,17,54].
To the best of our knowledge, only one case report where CEUS was performed on a parathyroid carcinoma has been published. In such a case, CEUS was highly suggestive of malignancy, with early heterogeneous enhancement and a homogeneous early wash-out [55].
Differences in the histopathological structures of normal and adenomatous PGs are responsible for the variations of gland stiffness detectable with USE. Indeed, because of their reduced fat-tissue components and external fibrous hard capsules, parathyroid adenomas display a significantly increased stiffness compared with normal and hyperplastic PGs, but a reduced stiffness when compared with parathyroid carcinoma (Figure 2b) [19,20].
The identification of an intrathyroidal parathyroid adenoma can be challenging. Characteristically it appears as a solid, profoundly hypoechoic nodule compared with other thyroid nodules or thyroid parenchyma, partially or fully enveloped with thyroid tissue, and a polar feeding vessel identified on Color Doppler US. The operator should be more suspicious of an intrathyroidal parathyroid adenoma especially in front of a patient with high clinical and biochemical probability of HPT when a nodule with these characteristics is noted and an extrathyroidal parathyroid adenoma is not visualized [56].
In cases of suspected ectopic PGs, the combination of the US with other radiological techniques, such as 99mTc-Sestamibi scintigraphy and magnetic-resonance imaging (MRI), must be considered as this has a clear advantage in improving preoperative imaging accuracy, allowing for a minimally invasive surgical approach for patient’s treatment [50]. Table 1 summarizes the main US characteristics of parathyroid lesions.

4. Ultrasound Mimics of Parathyroid Glands

Several neck structures may show visual similarities with enlarged PGs so that to differentiate them on a conventional US can represent a compelling challenge for the clinician [57]. As reported by numerous authors, each neck structure presents characteristic vascularization patterns and elasticity [19,58]. According to this evidence, the multiparametric US turns out to be very useful in differentiating enlarged PGs from other lesions such as thyroid nodules, neck lymph nodes, or paragangliomas.
Conventional US sensitivity is particularly low when the parathyroid disease is associated with goiter, especially when thyroid nodules are located posteriorly [59]. The reported prevalence of PHPT in combination with thyroid pathologies ranges from 17% to 84%; in this case, the preoperative PGs localization is known to have lower sensitivity and specificity [60]. In fact, enlarged PGs next to the thyroid poles might be misinterpreted as a part of the thyroid tissue [61]. Benign thyroid nodules present fast-in and slow-out homogeneous, intense smooth-rim enhancement on CEUS evaluation. In cases of malignancy, heterogeneous peripheral hypoenhancement in combination with internal enhancement patterns and a slow wash-in and wash-out curve lower than in normal thyroid tissue can be observed [62]. As for the USE examination, due to the fact that the thyroid gland is mainly composed of colloid-filled follicles, its appearance is soft [63]. Benign thyroid nodules appear softer than malignant ones and parathyroid adenomas [64,65]. Malignant thyroid nodules tend to have a higher stiffness compared with parathyroid adenomas, but lower compared with parathyroid carcinoma [19,64].
Perithyroidal lymph nodes, which are often identified in cases of chronic lymphocytic thyroiditis, may be factors leading to false-positive diagnoses of parathyroid incidentalomas [66]. In this context, the vascular pattern evaluation through Color Doppler US may be helpful for an appropriate differential diagnosis. Indeed, while PGs usually show polar feeding vessels, cervical lymph nodes characteristically present a hilar blood supply with feeding vessel entering the hilum centrally (Figure 3) [67].
However, these findings are not common in all parathyroid lesions and cervical lymph nodes [68]. Benign cervical lymph nodes generally display centrifugal and homogenous enhancement on CEUS evaluation. Conversely, according to their histopathologic changes, most metastatic/neoplastic lymph nodes are characterized by centripetal enhancement [69]. USE can be useful in distinguishing parathyroid lesions from cervical lymph nodes too, the former appearing significantly stiffer than the latter [70].
Paragangliomas are a rare form of slowly growing but potentially locally invasive, highly vascularized, neuroendocrine neoplasms arising from the chromaffin cells of sympathetic or parasympathetic paraganglia and accounting for the 0.6% of all head and neck tumors [71].
At the B-mode US, neck paragangliomas generally appear as well-defined hypoechoic masses that displace the carotid bifurcation, but can also show mixed echogenicity (Figure 4a) [14,72]. With Color Doppler imaging, an increased vascularity with a low-resistance flow pattern is generally evident, which can be predominantly peripheral with centripetal vessels inside the lesion [14]; however, a case of avascular paraganglioma is reported in literature [72] (Figure 4b). There is still limited evidence about CEUS appearance of neck paragangliomas [72,73]; these lesions normally show a strong and homogeneous contrast enhancement, such as that of the internal carotid artery, and a slow and progressive wash-out may be reported [14]. A clear and defined USE pattern has not been identified yet; the tumor can be both soft and hard [14] (Figure 4c).
Branchial cleft cysts, benign lesions caused by the anomalous development of the branchial apparatus during embryogenesis, must be considered in the differential diagnosis. Anomalies of the second branchial cleft account for approximately 90% of all cases and sonographically typically present as round-oval, hypo- to anechoic masses with well-defined margins, thin walls, and posterior wall enhancement, which compress the surrounding soft tissues [74]. However, there is variability in their US appearance. In fact, in the presence of infections or abscesses, the content of the cyst may become corpuscular, resulting in a pseudo-solid heterogeneous appearance [75] (Figure 5a,b). No published data are available about their USE appearance, but in consideration of its histopathological features, it is presumable that they will present as soft as cysts of other nature (Figure 5c).
Hemangiomas are common benign vascular tumors characterized by the abnormal proliferation of endothelial cells and abnormal blood vessel structures which, unless thrombosed, have characteristic imaging features [76]. On the grey-scale US, hemangiomas usually appear as solid hyperechogenic masses, with central hypoechogenicity and echogenic capsule. At the Color Doppler US, they show a rich vascular density with a prominent high-velocity arterial flow [76]. In large hemangiomas, an US is usually combined with a cross-sectional MRI for further evaluations of neighboring vital structures, such as the upper aerodigestive tract and the cervical vessels [77].

5. Complementary Imaging Techniques

The identification of hyperfunctioning PGs is mandatory for an adequate treatment of HPT, and in most of cases a stepwise approach with US and subsequent 99mTc-Sestamibi SPECT/CT is the first-line imaging strategy [2,78]. In cases of negative or inconclusive conventional imaging methods, 18F-fluorocholine PET/CT with its high spatial resolution, low radiation burden and short scanning time has been proposed as an alternative first-line “one-stop-shop” imaging method [7]; nevertheless, data on cost-effectiveness are currently lacking [2,78]. A further reduction of radial exposure can be obtained by the combination of 18F-fluorocholine PET and MRI [2,78]. Moreover, 18F-fluorocholine PET/MRI can be particularly useful in patients with low 18F-fluorocholine uptake [79], as well as in patients with discordant or inconclusive results of standard imaging methods [2,78]. However, 18F-fluorocholine PET/MRI-integrated systems are not widely available. Patients with a distorted cervical and chest anatomy or with small ectopical hyperfunctioning PGs may benefit from a four-dimensional (4D)-CT, which has a comparable sensitivity to 99mTc-Sestamibi SPECT/CT, with the drawback of a relatively low specificity and a significant radiation burden [2,78]. A combination of 18F-fluorocholine PET and 4D-CT can be useful in complicated cases, being superior to 18F-fluorocholine PET and 4D-CT alone in the localization of the hyperfunctioning PG [80]. MRI alone can be a viable choice as a second-line imaging technique; however, this can be considered as a first-line strategy in pregnant women [2,78].

6. Conclusions

For most of other neck organic disorders, the US cervical examination is the first-choice imaging tool for HPT-affected patients. Regardless of HPT etiology, surgical treatment is the recommended management strategy in patients meeting the international guidelines criteria and with no contraindications [81]. Bilateral neck exploration has been a widely used method for many years, but in the last decade it has been increasingly replaced by the minimal invasive parathyroidectomy approach because of the latter’s smaller extent, shorter duration, and lower rates of complications. However, surgery efficacy strictly depends on the precise localization of the pathological parathyroid tissue using preoperative imaging techniques. Despite newer emerging radiological investigations, cervical US and scintigraphy remain the main methods used for this purpose [81].
There is no doubt that the preoperative US assessment of HPT patients has many advantages, such as low costs, high availability, no patient exposure to ionizing radiation, and good visualization of the neck morphology. In most situations its sensitivity and specificity match those of other imaging techniques, but it should be noted that there are some limitations too, as in cases of uncommon PGs features and locations and the presence of anterior cervical mimics that may represent pitfalls in the US differential diagnosis of parathyroid diseases.
In these cases, a multiparametric approach, including beside the conventional US and other imaging techniques such as CEUS and USE, can be helpful, and should be adopted to guide a proper work-up.

Author Contributions

Conceptualization, R.C., F.S. and E.G.; writing—original draft preparation, R.C.; writing—review and editing, F.S., T.F., V.S., C.P., M.D.S., P.P., V.C. and E.G.; supervision, E.G., V.C. and M.G.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. McQueen, A.S.; Bhatia, K.S. Head and neck ultrasound: Technical advances, novel applications and the role of elastography. Clin. Radiol. 2018, 73, 81–93. [Google Scholar] [CrossRef] [PubMed]
  2. Ovčariček, P.P.; Giovanella, L.; Gasset, I.C.; Hindié, E.; Huellner, M.W.; Luster, M.; Piccardo, A.; Weber, T.; Talbot, J.-N.; Verburg, F.A. The EANM practice guidelines for parathyroid imaging. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2801–2822. [Google Scholar] [CrossRef] [PubMed]
  3. American Institute of Ultrasound in Medicine. AIUM Practice Guideline for the performance of thyroid and parathyroid ultrasound examination. J. Ultrasound. Med. 2003, 22, 1126–1130.
  4. Korwar, V.; Chang, F.Y.; Teasdale, E.; Suchett-Kaye, I.; Edwards, A.; Morgan, J. Stepwise Approach for Parathyroid Localisation in Primary Hyperparathyroidism. World J. Surg. 2020, 44, 803–809. [Google Scholar] [CrossRef] [PubMed]
  5. Yeh, M.W.; Barraclough, B.M.; Sidhu, S.B.; Sywak, M.S.; Barraclough, B.H.; Delbridge, L.W. Two hundred consecutive parathyroid ultrasound studies by a single clinician: The impact of experience. Endocr. Pract. 2006, 12, 257–263. [Google Scholar] [CrossRef]
  6. Udelsman, R.; Lin, Z.; Donovan, P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann. Surg. 2011, 253, 585–591. [Google Scholar] [CrossRef]
  7. Giovanella, L.; Bacigalupo, L.; Treglia, G.; Piccardo, A. Will (18)F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging? Endocrine 2021, 71, 285–297. [Google Scholar] [CrossRef]
  8. Treglia, G.; Giovannini, E.; Di Franco, D.; Calcagni, M.L.; Rufini, V.; Picchio, M.; Giordano, A. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: A systematic review. Ann. Nucl. Med. 2012, 26, 451–461. [Google Scholar] [CrossRef]
  9. Quak, E.; Blanchard, D.; Houdu, B.; Le Roux, Y.; Ciappuccini, R.; Lireux, B.; de Raucourt, D.; Grellard, J.-M.; Licaj, I.; Bardet, S.; et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: The APACH1 study. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 658–666. [Google Scholar] [CrossRef] [Green Version]
  10. Cantisani, V.; D’Ambrosio, F.; Nielsen, M.B. Multiparametric Ultrasound of Thyroid Nodules: Where Do We Stand? Ultraschall. Med. 2017, 38, 357–359. [Google Scholar] [CrossRef]
  11. Drudi, F.M.; Cantisani, V.; Angelini, F.; Ciccariello, M.; Messineo, D.; Ettorre, E.; Liberatore, M.; Scialpi, M. Multiparametric MRI Versus Multiparametric US in the Detection of Prostate Cancer. Anticancer Res. 2019, 39, 3101–3110. [Google Scholar] [CrossRef]
  12. Sidhu, P.S. Multiparametric Ultrasound (MPUS) Imaging: Terminology Describing the Many Aspects of Ultrasonography. Ultraschall. Med. 2015, 36, 315–317. [Google Scholar] [CrossRef]
  13. Cantisani, V.; Wilson, S.R. CEUS: Where are we in 2015? Eur. J. Radiol. 2015, 84, 1621–1622. [Google Scholar] [CrossRef]
  14. Pacini, P.; Polti, G.; Faggiano, A.; Giannetta, E.; Tarsitano, M.G.; Cantisani, V. Multiparametric ultrasound evaluation of a case of bilateral carotid body tumor. J. Ultrasound. 2021, 24, 311–315. [Google Scholar] [CrossRef]
  15. Yen, H.H. Progress in the Ultrasonographic Microvascular Imaging. J. Med. Ultrasound. 2018, 26, 1–2. [Google Scholar] [CrossRef]
  16. Parra Ramirez, P.; Santiago Hernando, A.; Barquiel Alcala, B. Potential Utility of Contrast-Enhanced Ultrasound in the Preoperative Evaluation of Primary Hyperparathyroidism. J. Ultrasound. Med. 2019, 38, 2565–2571. [Google Scholar] [CrossRef]
  17. Pavlovics, S.; Radzina, M.; Niciporuka, R. Contrast-Enhanced Ultrasound Qualitative and Quantitative Characteristics of Parathyroid Gland Lesions. Medicina 2021, 58, 2. [Google Scholar] [CrossRef]
  18. Azizi, G.; Piper, K.; Keller, J.M.; Mayo, M.L.; Puett, D.; Earp, K.M.; Malchoff, C.D. Shear wave elastography and parathyroid adenoma: A new tool for diagnosing parathyroid adenomas. Eur. J. Radiol. 2016, 85, 1586–1593. [Google Scholar] [CrossRef] [Green Version]
  19. Isidori, A.M.; Cantisani, V.; Giannetta, E. Multiparametric ultrasonography and ultrasound elastography in the differentiation of parathyroid lesions from ectopic thyroid lesions or lymphadenopathies. Endocrine 2017, 57, 335–343. [Google Scholar] [CrossRef]
  20. Ünlütürk, U.; Erdoğan, M.F.; Demir, Ö.; Çulha, C.; Gullu, S.; Başkal, N. The role of ultrasound elastography in preoperative localization of parathyroid lesions: A new assisting method to preoperative parathyroid ultrasonography. Clin. Endocrinol. 2012, 76, 492–498. [Google Scholar] [CrossRef]
  21. Trimboli, P.; D’Aurizio, F.; Tozzoli, R.; Giovanella, L. Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clin. Chem. Lab. Med. 2017, 55, 914–925. [Google Scholar] [CrossRef] [PubMed]
  22. Norman, J.; Politz, D.; Browarsky, I. Diagnostic aspiration of parathyroid adenomas causes severe fibrosis complicating surgery and final histologic diagnosis. Thyroid 2007, 17, 1251–1255. [Google Scholar] [CrossRef]
  23. Bancos, I.; Grant, C.S.; Nadeem, S.; Stan, M.N.; Reading, C.C.; Sebo, T.J.; Algeciras-Schimnich, A.; Singh, R.J. Risks and benefits of parathyroid fine-needle aspiration with parathyroid hormone washout. Endocr. Pract. 2012, 18, 441–449. [Google Scholar] [CrossRef] [PubMed]
  24. Lentsch, E.J.; Withrow, K.P.; Ackermann, D.; Bumpous, J.M. Parathyromatosis and recurrent hyperparathyroidism. Arch. Otolaryngol. Head Neck Surg. 2003, 129, 894–896. [Google Scholar] [CrossRef] [PubMed]
  25. Agarwal, G.; Dhingra, S.; Mishra, S.K.; Krishnani, N. Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch. Surg. 2006, 391, 623–626. [Google Scholar] [CrossRef]
  26. Bollerslev, J.; Schalin-Jäntti, C.; Rejnmark, L. Management of endocrine disease: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 2019, 181, P1–P19. [Google Scholar] [CrossRef] [Green Version]
  27. Fancy, T.; Gallagher, D., 3rd; Hornig, J.D. Surgical anatomy of the thyroid and parathyroid glands. Otolaryngol. Clin. North Am. 2010, 43, 221–227. [Google Scholar] [CrossRef]
  28. Carlson, D. Parathyroid pathology: Hyperparathyroidism and parathyroid tumors. Arch. Pathol. Lab. Med. 2010, 134, 1639–1644. [Google Scholar] [CrossRef]
  29. Duan, K.; Hernandez, K.G.; Mete, O. Clinicopathological correlates of hyperparathyroidism. J. Clin. Pathol. 2015, 68, 771–787. [Google Scholar] [CrossRef]
  30. Mazeh, H.; Kouniavsky, G.; Schneider, D.F.; Makris, K.I.; Sippel, R.S.; Dackiw, A.P.; Chen, H.; Zeiger, M.A. Intrathyroidal parathyroid glands: Small, but mighty (a Napoleon phenomenon). Surgery 2012, 152, 1193–1200. [Google Scholar] [CrossRef]
  31. Phitayakorn, R.; McHenry, C. Incidence and location of ectopic abnormal parathyroid glands. Am. J. Surg. 2006, 191, 418–423. [Google Scholar] [CrossRef]
  32. Taterra, D.; Wong, L.M.; Vikse, J.; Sanna, B.; Pękala, P.; Walocha, J.; Cirocchi, R.; Tomaszewski, K.; Henry, B.M. The prevalence and anatomy of parathyroid glands: A meta-analysis with implications for parathyroid surgery. Langenbecks Arch. Surg. 2019, 404, 63–70. [Google Scholar] [CrossRef] [Green Version]
  33. Ha, T.K.; Kim, D.W.; Jung, S.J. Ultrasound detection of normal parathyroid glands: A preliminary study. Radiol. Med. 2017, 122, 866–870. [Google Scholar] [CrossRef]
  34. Erickson, L.A.; Mete, O.; Juhlin, C.C.; Perren, A.; Gill, A.J. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr. Pathol. 2022, 33, 64–89. [Google Scholar] [CrossRef]
  35. Fraser, W.D. Hyperparathyroidism. Lancet 2009, 374, 145–158. [Google Scholar] [CrossRef]
  36. Pepe, J.; Cipriani, C.; Pilotto, R.; De Lucia, F.; Castro, C.; Lenge, L.; Russo, S.; Guarnieri, V.; Scillitani, A.; Carnevale, V.; et al. Sporadic and hereditary primary hyperparathyroidism. J. Endocrinol. Invest. 2011, 34, 40–44. [Google Scholar]
  37. Dugonjić, S.; Šišić, M.; Radulović, M.; Ajdinović, B. Positive (99m)Tc-MIBI and the subtraction parathyroid scan are related to intact parathyroid hormone but not to total plasma calcium in primary hyperparathyroidism. Hell J. Nucl. Med. 2017, 20, 46–50. [Google Scholar]
  38. El Lakis, M.; Nockel, P.; Gaitanidis, A. Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism. J. Am. Coll. Surg. 2018, 226, 933–938. [Google Scholar] [CrossRef]
  39. Jamal, S.A.; Miller, P.D. Secondary and tertiary hyperparathyroidism. J. Clin. Densitom. 2013, 16, 64–68. [Google Scholar] [CrossRef]
  40. Nasrallah, M.P.; Fraker, D.L.; LiVolsi, V.A. Parathyroid carcinoma in the setting of tertiaryhyperparathyroidism after renal transplant. Endocr. Pathol. 2014, 25, 433–435. [Google Scholar] [CrossRef]
  41. Moe, S.M. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur. J. Clin. Invest. 2006, 36, 51–62. [Google Scholar] [CrossRef] [PubMed]
  42. Huppert, B.J.; Reading, C.C. Parathyroid sonography: Imaging and intervention. J. Clin. Ultrasound. 2007, 35, 144–155. [Google Scholar] [CrossRef] [PubMed]
  43. Trimboli, P.; Dietrich, C.F.; David, E.; Mastroeni, G.; Spagnolo, O.V.; Sidhu, P.; Letizia, C.; Messineo, D.; D’Ambrosio, F.; Radzina, M.; et al. Ultrasound and ultrasound-related techniques in endocrine diseases. Minerva Endocrinol. 2018, 43, 333–340. [Google Scholar] [CrossRef] [PubMed]
  44. Guilmette, J.; Sadow, P.M. Parathyroid Pathology. Surg. Pathol. Clin. 2019, 12, 1007–1019. [Google Scholar] [CrossRef] [PubMed]
  45. Acar, T.; Ozbek, S.S.; Ertan, Y.; Kavukcu, G.; Tuncyurek, M.; Icoz, R.G.; Akyildiz, M.M.; Makay, O.; Acar, S. Variable sonographic spectrum of parathyroid adenoma with a novel ultrasound finding: Dual concentric echo sign. Med. Ultrason. 2015, 17, 139–146. [Google Scholar] [CrossRef] [Green Version]
  46. Mohammadi, A.; Moloudi, F.; Ghasemi-rad, M. The role of colour Doppler ultrasonography in the preoperative localization of parathyroid adenomas. Endocr. J. 2012, 59, 375–382. [Google Scholar] [CrossRef] [Green Version]
  47. Vitetta, G.M.; Ravera, A.; Mensa, G.; Fuso, L.; Neri, P.; Carriero, A.; Cirillo, S. Actual role of color-doppler high-resolution neck ultrasonography in primary hyperparathyroidism: A clinical review and an observational study with a comparison of (99m)Tc-sestamibi parathyroid scintigraphy. J. Ultrasound. 2019, 22, 291–308. [Google Scholar] [CrossRef]
  48. Hayakawa, N.; Nakamoto, Y.; Kurihara, K.; Yasoda, A.; Kanamoto, N.; Miura, M.; Inagaki, N.; Togashi, K. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nucl. Med. Commun. 2015, 36, 53–59. [Google Scholar] [CrossRef] [Green Version]
  49. Ruda, J.M.; Hollenbeak, C.S.; Stack, B.C., Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol. Head Neck Surg. 2005, 132, 359–372. [Google Scholar] [CrossRef]
  50. Xue, J.; Liu, Y.; Ji, T.; Zhao, A.; Liang, Y.; Deng, H.; Wang, Q.; Zhang, Y.; Yang, L.; Yang, A. Comparison between technetium-99m methoxyisobutylisonitrile scintigraphy and ultrasound in the diagnosis of parathyroid adenoma and parathyroid hyperplasia. Nucl. Med. Commun. 2018, 39, 1129–1137. [Google Scholar] [CrossRef]
  51. Strambu, V.; Bratucu, M.; Garofil, D.; Paic, V.; Zurzu, M.; Tigora, A.; Popa, F.; Radu, P. The Value of Imaging of the Parathyroid Glands in Secondary Hyperparathyroidism. Chirurgia 2019, 114, 541–549. [Google Scholar] [CrossRef]
  52. Liu, J.; Zhan, W.; Zhou, J.; Zhou, W. Role of ultrasound in the differentiation of parathyroid carcinoma and benign parathyroid lesions. Clin. Radiol. 2020, 75, 179–184. [Google Scholar] [CrossRef]
  53. Sidhu, P.S.; Talat, N.; Patel, P.; Mulholland, N.J.; Schulte, K.-M. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: A retrospective analysis of parathyroid tumours larger than 15 mm. Eur. Radiol. 2011, 21, 1865–1873. [Google Scholar] [CrossRef]
  54. Platz Batista da Silva, N.; Jung, E.M.; Jung, F. VueBox(R) perfusion analysis of contrast-enhanced ultrasound (CEUS) examinations in patients with primary hyperparathyroidism for preoperative detection of parathyroid gland adenoma. Clin. Hemorheol. Microcirc. 2018, 70, 423–431. [Google Scholar] [CrossRef]
  55. Ratniece, M.; Tauvena, E.; Pavlovics, S.; Niciporuka, R.; Liepa, M.; Prieditis, P.; Ozolins, A.; Gardovskis, J.; Radzina, M.; Narbuts, Z. Large Parathyroid Tumor 8 Years after Thyroid Surgery: A Case Report. Case Rep. Oncol. 2022, 15, 528–534. [Google Scholar] [CrossRef]
  56. Heller, M.T.; Yip, L.; Tublin, M.E. Sonography of intrathyroid parathyroid adenomas: Are there distinctive features that allow for preoperative identification? Eur. J. Radiol. 2013, 82, e22–e27. [Google Scholar] [CrossRef]
  57. Kuzminski, S.J.; Sosa, J.A.; Hoang, J.K. Update in Parathyroid Imaging. Magn. Reson. Imaging Clin. N Am. 2018, 26, 151–166. [Google Scholar] [CrossRef]
  58. Trimboli, P.; Castellana, M.; Virili, C.; Havre, R.F.; Bini, F.; Marinozzi, F.; D’Ambrosio, F.; Giorgino, F.; Giovanella, L.; Prosch, H.; et al. Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: A systematic review and meta-analysis using histological standard of reference. Radiol. Med. 2020, 125, 406–415. [Google Scholar] [CrossRef]
  59. Barbaros, U.; Erbil, Y.; Salmashoğlu, A. The characteristics of concomitant thyroid nodules cause false-positive ultrasonography results in primary hyperparathyroidism. Am. J. Otolaryngol. 2009, 30, 239–243. [Google Scholar] [CrossRef]
  60. Scerrino, G.; Attard, M.; Piccolo, C.L. The coexistence of primary hyperparathyroidism and thyroid nodules: Should the preoperative work-up of the parathyroid and the thyroid diseases be specifically adjusted? G. Chir. 2016, 37, 123–129. [Google Scholar] [CrossRef]
  61. Treglia, G.; Trimboli, P.; Huellner, M. Imaging in primary hyperparathyroidism: Focus on the evidence-based diagnostic performance of different methods. Minerva Endocrinol. 2018, 43, 133–143. [Google Scholar] [CrossRef] [PubMed]
  62. Radzina, M.; Ratniece, M.; Putrins, D.S.; Saule, L.; Cantisani, V. Performance of Contrast-Enhanced Ultrasound in Thyroid Nodules: Review of Current State and Future Perspectives. Cancers 2021, 13, 5469. [Google Scholar] [CrossRef] [PubMed]
  63. Rago, T.; Scutari, M.; Santini, F. Real-time elastosonography: Useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology. J. Clin. Endocrinol. Metab. 2010, 95, 5274–5280. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Batur, A.; Atmaca, M.; Yavuz, A.; Ozgokce, M.; Bora, A.; Bulut, M.D.; Arslan, H.; Toktas, O.; Alpaslan, M. Ultrasound Elastography for Distinction Between Parathyroid Adenomas and Thyroid Nodules. J. Ultrasound. Med. 2016, 35, 1277–1282. [Google Scholar] [CrossRef]
  65. Chandramohan, A.; Therese, M.; Abhraham, D. Can ARFI elastography be used to differentiate parathyroid from thyroid lesions? J. Endocrinol. Invest. 2018, 41, 111–119. [Google Scholar] [CrossRef] [Green Version]
  66. Ghervan, C.; Silaghi, A.; Nemes, C. Parathyroid incidentaloma detected during thyroid sonography—Prevalence and significance beyond images. Med. Ultrason. 2012, 14, 187–191. [Google Scholar]
  67. Rohan, K.; Ramesh, A.; Sureshkumar, S. Evaluation of B-Mode and Color Doppler Ultrasound in the Diagnosis of Malignant Cervical Lymphadenopathy. Cureus 2020, 12, e9819. [Google Scholar] [CrossRef]
  68. Liu, H.; Liao, Q.; Wang, Y.; Hu, Y.; Zhu, Q.; Wang, L.; Liu, Q.; Li, J.; Jiang, Y. A new tool for diagnosing parathyroid lesions: Angio plus ultrasound imaging. J. Thorac. Dis. 2019, 11, 4829–4834. [Google Scholar] [CrossRef]
  69. Chen, L.; Chen, L.; Liu, J. Value of Qualitative and Quantitative Contrast-Enhanced Ultrasound Analysis in Preoperative Diagnosis of Cervical Lymph Node Metastasis from Papillary Thyroid Carcinoma. J. Ultrasound. Med. 2020, 39, 73–81. [Google Scholar] [CrossRef]
  70. Cotoi, L.; Borcan, F.; Sporea, I.; Amzar, D.; Schiller, O.; Schiller, A.; Dehelean, C.A.; Pop, G.N.; Stoian, D. Shear Wave Elastography in Diagnosing Secondary Hyperparathyroidism. Diagnostics 2019, 9, 213. [Google Scholar] [CrossRef] [Green Version]
  71. Mete, O.; Asa, S.L.; Gill, A.J.; Kimura, N.; de Krijger, R.R.; Tischler, A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr. Pathol. 2022, 33, 90–114. [Google Scholar] [CrossRef]
  72. Rubenthaler, J.; Lutz, J.; Reiser, M. Title Page—Paraganglioma of the Head and Neck: Follow-Up of Interventional Procedures with CEUS. Ultraschall. Med. 2015, 36, 541–543. [Google Scholar]
  73. Puliani, G.; Sesti, F.; Feola, T.; Di Leo, N.; Polti, G.; Verrico, M.; Modica, R.; Colao, A.; Lenzi, A.; Isidori, A.M.; et al. Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. J. Clin. Med. 2020, 9, 588. [Google Scholar] [CrossRef] [Green Version]
  74. Valentino, M.; Quiligotti, C.; Carone, L. Branchial cleft cyst. J. Ultrasound. 2013, 16, 17–20. [Google Scholar] [CrossRef] [Green Version]
  75. Ahuja, A.T.; King, A.D.; Metreweli, C. Second branchial cleft cysts: Variability of sonographic appearances in adult cases. AJNR Am. J. Neuroradiol. 2000, 21, 315–319. [Google Scholar]
  76. Sadick, M.; Overhoff, D.; Baessler, B.; von Spangenberg, N.; Krebs, L.; Wohlgemuth, W.A. Peripheral Vascular Anomalies—Essentials in Periinterventional Imaging. Rofo 2020, 192, 150–162. [Google Scholar] [CrossRef]
  77. Majewska, N.K.; Stajgis, P.; Wykrętowicz, M. Peripheral vascular malformations—Modern imaging. Pol. J. Radiol. 2018, 83, e253–e259. [Google Scholar] [CrossRef]
  78. Ovčariček, P.P.; Giovanella, L.; Hindie, E.; Huellner, M.W.; Talbot, J.-N.; Verburg, F.A. An essential practice summary of the new EANM guidelines for parathyroid imaging. Q J. Nucl. Med. Mol. Imaging 2022, 66, 93–103. [Google Scholar]
  79. Alharbi, A.A.; Alshehri, F.M.; Albatly, A.A. [(18)F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level. Mol. Imaging Biol. 2018, 20, 857–867. [Google Scholar] [CrossRef]
  80. Piccardo, A.; Trimboli, P.; Rutigliani, M. Additional value of integrated (18)F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 766–775. [Google Scholar] [CrossRef]
  81. Bilezikian, J.P.; Khan, A.A.; Silverberg, S.J. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J. Bone Miner Res. 2022, 37, 2293–2314. [Google Scholar] [CrossRef] [PubMed]
Jcm 12 02487 g001a 550Jcm 12 02487 g001b 550
Figure 1. Grey-scale (a,b,d) and Color Doppler (c,e) aspect of a parathyroid adenoma.
Figure 1. Grey-scale (a,b,d) and Color Doppler (c,e) aspect of a parathyroid adenoma.
Jcm 12 02487 g001aJcm 12 02487 g001b
Jcm 12 02487 g002 550
Figure 2. Grey-scale (a) and elastography (b) aspect of a hyperplastic parathyroid gland (arrow).
Figure 2. Grey-scale (a) and elastography (b) aspect of a hyperplastic parathyroid gland (arrow).
Jcm 12 02487 g002
Jcm 12 02487 g003 550
Figure 3. Grey-scale (a) and Color Doppler (b) aspect of cervical lymph node.
Figure 3. Grey-scale (a) and Color Doppler (b) aspect of cervical lymph node.
Jcm 12 02487 g003
Jcm 12 02487 g004 550
Figure 4. Grey-scale (a), Color Doppler (b) and elastography (c) aspect of a carotid body paraganglioma.
Figure 4. Grey-scale (a), Color Doppler (b) and elastography (c) aspect of a carotid body paraganglioma.
Jcm 12 02487 g004
Jcm 12 02487 g005 550
Figure 5. Grey-scale (a), Color Doppler (b) and elastography (c) aspect of a infected second branchial cleft cyst.
Figure 5. Grey-scale (a), Color Doppler (b) and elastography (c) aspect of a infected second branchial cleft cyst.
Jcm 12 02487 g005
Table
Table 1. Ultrasound (US) features of parathyroid lesions on B-Mode, Color Doppler, contrast-enhanced US (CEUS), and US-elastography (USE) examination.
Table 1. Ultrasound (US) features of parathyroid lesions on B-Mode, Color Doppler, contrast-enhanced US (CEUS), and US-elastography (USE) examination.
B-ModeColor Doppler USCEUSUSE
Parathyroid hyperplasiaMore than one symmetrically or asymmetrically enlarged, hypoechoic, oval shaped, lobulated gland.
Significantly smaller than adenoma.
Cystic inclusions may be seen.		Feeding polar vessels entering the pole and then extending around the periphery.Fast intense homogeneous enhancement.
Fast homogeneous wash-out.		Stiffer than proper parathyroid glands.
Parathyroid
adenoma		Enlarged, circumscribed, hypoechoic, oval shaped lesion, delineated by hyperechoic halo.
Cystic inclusions may be seen.		Feeding polar vessels entering the pole and then extending around the periphery.Early peripheral hyperenhancement.
Central wash-out in the later phases.		Stiffer than hyperplastic parathyroid glands.
Parathyroid carcinomaLength > 3 cm, depth/width ratio > 1.
Lobulated, heterogeneous, hypoechoic lesion.
Irregular borders.
Thick capsule.
Intranodular calcifications.
Cystic inclusions may be seen.		Intralesional disordered vascularity.Early heterogeneous enhancement.
Early homogeneous wash-out.		Stiffer than proper, hyperplastic, and adenomatous parathyroid glands.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Centello, R.; Sesti, F.; Feola, T.; Sada, V.; Pandozzi, C.; Di Serafino, M.; Pacini, P.; Cantisani, V.; Giannetta, E.; Tarsitano, M.G. The Dark Side of Ultrasound Imaging in Parathyroid Disease. J. Clin. Med. 2023, 12, 2487. https://doi.org/10.3390/jcm12072487

AMA Style

Centello R, Sesti F, Feola T, Sada V, Pandozzi C, Di Serafino M, Pacini P, Cantisani V, Giannetta E, Tarsitano MG. The Dark Side of Ultrasound Imaging in Parathyroid Disease. Journal of Clinical Medicine. 2023; 12(7):2487. https://doi.org/10.3390/jcm12072487

Chicago/Turabian Style

Centello, Roberta, Franz Sesti, Tiziana Feola, Valentina Sada, Carla Pandozzi, Marco Di Serafino, Patrizia Pacini, Vito Cantisani, Elisa Giannetta, and Maria Grazia Tarsitano. 2023. "The Dark Side of Ultrasound Imaging in Parathyroid Disease" Journal of Clinical Medicine 12, no. 7: 2487. https://doi.org/10.3390/jcm12072487

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop